- Hematologic (Blood Cancers)
Objective:
Primary Objectives:
To evaluate ORR of pirtobrutinib (Arm A) compared to ibrutinib (Arm B)
Secondary Objectives:
To evaluate the effectiveness of Arm A compared to Arm B based on EFS, PFS, ORR, DOR, OS, and TTNT
To evaluate the safety and tolerability of each treatment arm
To evaluate the patient-reported outcomes of Arm A compared to Arm B